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The skin is a major target organ for graft-versus-host disease 
(GVHD), the principal complication of allogeneic bone 
marroW transplantation. The purpose of the present study 
was to test whether mast cell degranulation might be related 
to early target cell il~ury in the development of acute 
GVHD. We employed two irradiated murine strain combi-
nations, one in which disease was mediated by CD4+ effector 
T cells (BI0.D2 ---+ DBA/2), and the other by CD8+ effector 
T cells (BIO.BR ---+ CBA). As compared to controls, both 
models exhibited mast cell degranulation of differing extents 
and patterns, as well as dyskeratosis in the epidermis be-
fore the influx of effector lymphocytes. These results sug-
gested that factors produced and released by degranulated 
dermal mast cells might contribute to early target cell injury. 
Accordingly, the possible role of tumor necrosis factor 
(TN F)-a, a cytokine recently discovered in mast cell gran-
ules, was investigated by the injection of anti- TNF-a anti-
body during the course of disease mediated by either CD4+ or 
A cute graft-versus-host disease (GVHD) is a major complication of allogeneic bone marrow trans~lanta­tion, with the skin a primary target organ [1 J. The immunopathogenesis of GVHD, however, is still largely unknown, and the precise nature of the effec-
tor cells and their functional activity resulting in epithelial damage 
rem.ain controversial. It has been generally thought that in GVHD, 
cytotoxic donor T cells (primarily CD8+, although CD4+ cells 
potentially exhibit overlapping functional activity) may directly 
destroy host target cells that reside in lympho-hematopoietic 
organs, the liver, the gastrointestinal tract, and the skin [2,3]. Alter-
natively, alloreactive T cells may produce localized inflammatory 
responses by release of cytokines that either damage tissue directly 
or produce injury by activation of non-specific inflammatory cells 
secondarily recruited to the site [4-6) . A likely candidate cytokine 
for induction of epithelial injury and associated inflammation in 
GVHD is tumor necrosis factor a (TNF-a), which is present in the 
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CD8+ T cells. Although overall survival of recipients under-
going CD4 + T -cell- mediated GVHD was only slightly im-
proved and the extent of mast cell degranulation was not 
affected by anti - TNF-a antibody treatment, the skin exhib-
ited a significant diminution in the number of dyskeratotic 
cells/linear mm at 3 - 4 weeks post-transplantation. In con-
trast, anti- TNF-a antibody failed to enhance survival or 
reduce the number of dyskeratotic cells in the skin during 
CD8+ T -cell- mediated disease. Finally, to determine 
whether CD8+ T-cell-mediated GVHD was at all depen-
dent upon mast cell involvement, the C3H.SW ---+ B6 WWv 
strain combination was utilized, in which recipients were 
genetically deficient in mast cells . Onset of GVHD was sig-
nificantly delayed in B6WWv mice and was clearly corre-
lated to the appearance and increase of de tlOllO mast cells at 
later time points. Key words: mast cells/graJt-versus-host disease/ 
target cell injury. ] Invest Dermatol1 02:451- 461, 1994 
serum of experimental animals with GVHD at times of peak epi-
thelial injury [4]. Moreover, anti- TNF-a antibodies almost en-
tirely prevented the cutaneous and intestinal epithelial lesions with 
reduced overall mortality in a murine GVHD model [5,7). 
At the cellular level, mast cells that normally populate subepithe-
lial con.nective ~issue (e.g., skin, oropharynx, esophagus) and muco-
sallamma propla (e.g., gut) may playa role in GVHD pathogenesis 
~ecause s~imulate~ CD4+ and CD8+ T cells secrete cytokines, par-
ticularly mterleuk!11 (IL)-3, that affect mast cell growth, activation, 
and relea.se of mediators [8,9]. Electron microscopy studies of mast 
cells in the skin of mice undergoing GVHD have indicated active 
secretion (10). Although it is not clear to what extent the different 
types of mast cell mediators produced have a bearing on the devel-
opment of disease, it is interesting to note that TNF-like factors can 
be produced by murine mast cells [11-13]. It has also been recently 
demonstrated that human dermal mast cells express TNF-a mRNA 
and that purified mast cells release more TNF-a protein through 
degranulation on a per-cell basis than endotoxin-stimulated mono-
cytes (14). In certain target cells, TNF-a has been shown to cause 
DNA fragmentation, which leads to programmed cell death, or 
apoptosis [15] . Murine recipients of the keratin 14 promoter-driven 
TNF-a trans gene have epithelial necrosis similar to that seen in 
acute GVHD (16). Therefore, it is possible that some of the early 
epithelial injury in experimental GVHD could result from local 
TNF-a released through mast cell-dependent pathways. 
In experimental murine models, T cells are required for the de-
velopment of lethal GVHD directed to multiple minor histocom-
patibility (H) antigens [17]. Previous investigations have indicated 
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that either CD4+ or CD8+ T-cell subsets are capable of mediating 
GVHD across minor H barriers, depending upon the particular 
strain combination utilized [1 8,19]. With use of highly purified 
preparations of donor T-cell subsets, CD8+ T cells, by themselves, 
were capable of mediating lethal disease in all strain combinations 
tested (e.g., Bl0.BR ....... CBA), whereas CD4+ T cells were potent 
effectors in only two strain combinations, one of which is the 
Bl0.D2 ....... DBA/2 model [18]. Pathologic examination of skin 
lesions induced by minor H antigenic differences in these strain 
combinations has revealed these models to be 1) similar to cutane-
ous GVHD in humans, 2) quantifiable according to the number 
of dyskeratotic cells/mm of epidermis 3) related in severity to 
the number of T cells in the donor marrow inocula, and 4) accu-
rate indicators of associated gastrointestinal and visceral disease 
[20 - 23]. 
In the present study, we utilized antibody-treated donor inocula 
to produce CD4+ and CD8+ T-cell - mediated GVHD and to char-
acterize further sequential alterations by ultrastructural and quanti-
tative analysis. Specifically, we attempted to clarify the role of mast 
cells and TNF in early epidermal injury and in subsequent effector 
cell recruitment during GVHD. Our results indicate that 1) degran-
ulation of mast cell s precedes vascular activation and subsequent 
influx of effector cells, 2) mast cells at early timepoints of CD4+ T 
and CD8+ T -cell- mediated GVHD display evidence of active de-
gra nulation or decreased numbers of granules, respectively, 
3) whereas early epithelial target cell injury (day 7 post-transplanta-
tion) is unaffected by the anti - TNF-a antibody (Ab) treatment in 
both models, passive immunization significantly reduces dyskerato-
sis at 3 - 4 weeks post-transplantation in CD4 + T -cell- mediated 
GVHD but not in disease mediated by CD8+ T cel ls, and 4) trans-
plantation of C3H.SW CD8+ effector T cells into irradiated mast 
cell- deficient B6 W /W v mice results in significantly delayed de-
velopment of GVHD pathologic changes when compared to con-
trol B6+/+ recipients, indicating a dcpendency upon mast cells for 
the developmcnt of CD8+ T-cell - mcdiated epithelial injury. 
Taken collcctively, these data suggest that mast cel ls may participate 
both directly and indirectly in the early pathogenesis of acute exper-
imental GVHD. 
MATERIALS AND METHODS 
Animals B10.BR/SgSn, Bl0.D2/oSnJ, CBA/J, C3H.SW ISnJ, DBA/ 
2J, WBB6F,/J-WIWv (B6WIWV ), and WBB6F,lr l+ (B6+1+ ) mice were 
purchased from the J ackson Laboratory (Bar Harbor, ME). Male mice were 
used as cell donors between 7 and 12 weeks of age and as recipients between 9 
and 16 weeks of age. Mice were always kept in a sterile environment in 
microisolator cages (Lab Products, Maywood, NJ) and provided with auto-
c1aved food and acidified water (pH 2.5). 
Monoclonal Antibodies (MoAbs) Ascites fluid for anti-Thy-1.2 (J1j, 
rat immunoglobulin [l g]M [24]), anti-CD4 (GK1.5, rat IgG2a [25], and 
RLl72, rat IgM [26]), anti-CD8 (3.168, rat IgM [27]), and supe~natant from 
anti -B-cel l (Jlld; rat IgM [24]) MoAbs were used. for cell prep.arations. 
Guinea pig serum was used as a source of complement (C) for all MoAb 
treatments. 
Preparation of Rabbit Antisera Rabbit anti-TNF-a antiserum and 
control rabbit IgG were prepared according to previously described proto-
cols [28]. In brief, five female New Zealand white rabbits (2 - 3 kg) were 
immunized with 50 mg of recombinant murine TNF-(I' emulsified in com-
plete Freund's adjuvant (CFA) supplemented with M. tuberculosis (H37Ra) at 
a concentration of 9 mg/ml. This emulsion was distributed il1tradermally 
(i .d.) among 10-12 sites on the back of each rabbit. All animals were boosted 
subcutaneously with 10 mg of recombinant murine TNF-(I' in incomplete 
Freund's adjuvant 20 d later and screened for the production of-:;!1\ti - TNF-(I' 
Abs using a solid-phase radioimmunoassay 30 d after the initial injection. All 
animals were found to be producing equivalent high titers of llnti - TNF-a 
antibody and were bled seria lly. Two rabbits were immunized with CFA and 
an irrelevant antigen. Their pooled serum served as the source of the control 
IgG. Rabbit anti-CFA IgG (CFA RIgG) and anti-murine TNf'-a IgG were 
purified by protein A sepharose (Pharmacia, Piscataway, NJ) affinity c1uo-
matography. The specificity ofthe anti- TNF-(I' Ab preparation was charac-
terized by W estern blot analysis. CFA RlgG control serum pools failed to 
demonstrate immunoreactivity with murine TNF-a in Western blots. In 
contrast, the anti - TNF-(I' antiserum pool exhibi ted specific ;mmunoreac-
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tivity with the immunogen. The efficacy of the purified anti - TNF-a IgG at 
blocking the biologic responses mediated by TNF-a was assessed in endo-
toxin protection assays as described previously [28]. 
Preparation of Donor Cells Donor cells were prepared according to 
previously described protocols [18]. In brief, bone marrow cells were ob-
tained from the femurs and tibiae of donor mice by flushing with buffered 
saline solution (BSS) supplemented with 0.1 % bovine serum albumin (BSA; 
Hyclone, Logan, UT). To prepare anti - Thy-l-treated (T-cell -depleted) 
bone marrow (ATBM), cells were incubated withJlj MoAb (diluted 1 : 100) 
and complement (C) (1: 25) for 45 min at 37"C, fo llowed by four washes. 
T -cell - enriched donor cell populations were prepared by treating pooled 
spleen and lymph node cells with the anti - B-cell J l1d MoAb (diluted 1 : 5) 
and C (1: 25) for 1 hat 37 ·C. This treatment generally resulted in a popula-
tion of between 90 and 95% Thy1 + cells, as measured for phenotyping by 
flow cytometric ana lysis . 
For preparation of purified T-cell subset populations, as described else-
where [18]. J 11 d pI us C-treated lymphocytes were further treated with 
appropriate MoAb and C directed against the undesirable subset. For exam-
ple, to purify CD4+ T cell s, lymphocytes were treated twice with anti-CD8 
MoAb (3.168; diluted 1 : 50) plus C (1: 25) for 45 min at 37"C, initially, and 
again for 30 min with a wash in between. After another wash, the cells « 1.5 
X 108) were placed on a Petri plate (150 mm, Falcon non-tissue culture 
grade) coated with GK1.5 anti-CD4 MoAb (preincubated for 1 h at room 
temperature with 15 ml of a 1 : 12,000 dilution of ascites fluid) in a volume 
of 8 ml BSS and kept stationary at 4 ' C for 1 h. N onadherent cells were 
poured off and the plate was washed 5 - 6 times by gentle swirling and 
pouring. Adherent CD4+ cells were then eluted by forceful pi petting. An 
analogous procedure was used to prepare purified CD8+ T cells, with the 
substitution of a single RL172 anti-CD4 MoAb plus C treatment, and a 
30-min incubation on ice of the ce lls with the anti-CD8 MoAb (1 : 50 
dilution) alone. Cells were then washed once and positively panned on a 
plate coated with goat anti-rat IgM Ab (preincubated with 1 : 200 dilution; 
Cooper Biomedical, Malvern, PAl. Eluted subsets were phenotyped by flow 
cytometry analysis and were rontinely found to be negative for the opposite 
subset. . 
GVHD Induction The Bl0.D2 ~ DBA/2 (900 cGy) stra in combina-
tion was used for studies with CD4+ T -cell-mediated GVHD, whereas the 
Bl0.BR ~ CBA (800 cGy), C3H.SW ~ B6WWv (850 cGy), and 
C3H.SW ~ B6+1+ (850 cGy) strain combinations were used for studies 
with CD8+ T-cell- mediated GVHD. Recipient mice were irradiated with 
the appropriate exposure from a Gammacell137Cs source (130 cGy/min). 
Approximately 6 h later, these recipients were injected intravenously with 
dOllor cel ls Virl the tail vein. The inoculum consisted of either ATBM cells 
(2 X 106) alone as a negative control, or a mixture of ATBM (2 X 106) 
together with either donor-purified CD4+ or CD8+ T cells (with dosage 
between 2 and 4 X 106 cell s, depending upon the particular strain combina-
tion) . Irradiated recipient mice were passively immunized by an initial intra-
venous injection of rabbit anti-mouse TNF-a Ab (2 mg) or control CFA 
RIgG, within 5 h after irradiation and 1 h before transplantation. Ab was 
then administered intra peritoneally (2 mg) on a weekly basis for up to 6 
weeks post-transplantation. Mice, which were treated with neither anti-
TNF-(I' Ab nor CFA RlgG, se rved as positive controls. Mortality was ob-
served daily for between 80 and 100 d. 
Biopsy Serial ear biopsies were performed on six animals (CD4+ effector 
series) or three animals (CD8+ effector series) for each experimental condi-
tion at each timepoint, beginning at the time of transplantation (day 0) and 
sequentially every 7 d thereafter until death or a maximnm of 42 d. Biopsies 
were fu ll thickness, measured 3 X 2 mm, and were taken from alternating 
sides. Attention was paid to avo id previous healing surgical wounds. 
Light and Electron Microscopy The specimens were immediately 
fixed in 4% glutara ldehyde overnight and then rinsed with 0.1 M sodium 
cacodylate buffer (pH 7.4). Tissues were postfixed with 2% osmium tetrox-
ide for 2 h, dehydrated in graded ethanol, and embedded in Epon 812. 
One-micron - thick sections were cut with a Porter-Blum MT2B ultrami-
crotome, stained with toluidine blue, and finally dipped in 95% ethanol for 
light microscopic ana lysis. 
The number of dyskeratotic epidermal cells/linear mm, which has been 
previously shown to correlate w ith disease severity and with number of 
transplanted T cells in this model of GVHD [21,23], was counted under a 
X 100 objective and a X 10 eyepiece of a light microscope. More than 10 
linear mm of the epidermis was assessed in each animal and at each time-
point. Extent of mast cel l degranulation was also evaluated under the same 
magnification, as follows: category I, < 25% of granules depleted; category 
n, 25 - 75% of granules depleted; and categoty III, > 75% of granules de-
pleted. Fully granulated mast ce lls, as defined by control skin, showed cyto-
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plastnic area to be entirely filled with darkly stained metachromatic gran-
ules. Granule depletion was evidenced by loss of metachromasia over 
portions of the cytoplasmic area. Because hypogranular mast cells could also 
represent dying or degenerating cells, confirmation of active degranulation 
and absence of degenerative alterations were established by transmission 
electron microscopy. More than 40 mast cel ls were evaluated in each animal 
and at each timepoint. Ear thickness, which paralleled the extent of dermal 
infiltration by leukocytes, was measured 1 mm beneath the top of the ear. 
For electron microscopy, ultrathin sections were cut with a Porter-Blum 
MT2B ultramicrotome. Sections were stained with uranyl acetate and bis-
muth, and observed in a Hitachi H-7000 electron microscope. 
Statistical Analysis Data were pooled from two separate experiments 
and involved the analysis of skin samples from between three and eight mice 
at each timepoint for the determination of the number of dyskeratotic cells 
per rnm, extent of mast cell degranulation, and ear thickness. Significant 
differences between experimental groups were determined using Fisher's 
least-significant difference test for the multiple analysis of variance. The 
GVHD mortality .assays representedrooled data. from two to three separ~te 
experiments and mvolved a total 0 14-18 ITI1Ce per group, and medIan 
survival time (MST) values were statistically compared by Wilcoxon non-
parametric rank analysis. 
RESULTS 
Biopsies from control recipients ofT -cell- depleted A TBM showed 
only small numbers of perivascular leukocytes and only rare exocy-
totic lymphoid cells and dyskeratotic epidermal cells. In contrast, 
skin from both CD4+ (BI0.D2 --. DBA/2 900 cGy) and CD8+ 
(BI 0.BR --. CBA 800 cGy) cell-mediated GVHD models demon-
strated a defined sequence of pathologic changes consisting of pro-
gressive leukocyte infiltration and dyskeratosis typical of cutaneous 
acute GVHD [23] . Leukocytes first appeared about superficial der-
mal vessels between days 14 and 21 post-transplantation, and epi-
dermal dyskeratosis and leukocyte exocytosis became prominent 
between days 21 and 35. . 
Early Alterations in GVHD: Days 0 -7 The first pathologic 
al teration observed by light or electron microscopy in either strain 
combination occurred at day 7 and consisted of evidence of mast cell 
degranulation in CD4+ cell-mediated disease (Fig 1) and hypogran-
ulated mast cells without evidence of active degranulation in CD8+ 
cell-mediated GVHD (Fig 2). Skin in both strain combinations at 
this juncture was devoid of leukocyte influx. Hypogranular mast 
cells in CD8+ cell-mediated GVHD showed no evidence of cyto-
plasmic or nuclear dege,:eration by ultrastructure~ suggesting t~at 
their state of degranulation was the result of prevIOus granule diS-
charge and not due to degenerative alterations. In both CD4+ and 
CD8+ cell-mediated disease, epidermal cells showed dyskeratosis in 
association with mast cell degranulation or hypogranulation. By 
kinetic analysis, the number of dyskeratotic cells per mm of skin 
increased equivalently over the time course of the study for both 
CD4+ (Fig 3b) and CD8+ (Fig 4b) cell-mediated GVHD, without 
statistical significance between disease caused by either donor T-cell 
subset (0.29 < P < 0.98). In contrast, marked differences between 
donor T-cell subsets were observed in the extent of mast cell de-
granulation by light microscopy, particularly on day 7 post-trans-
plantation (Figs 3c and 4c). Significantly more mast cells consistent 
with level II (involving 25 - 75% granule depletion; approximately 
a 2 X increase; p < 0.04) and level III (involving> 75% granule 
depletion; approximately a 3 X increase; p = 0.03) were evident in 
the CD4+ cell-mediated group (Fig 3c) as compared to the CD8+ 
cell-mediated group (Fig 4c) . In addition, the percentage of mast 
cells of CD8+ cell-mediated GVHD, consistent with level I (in-
volving <25% granule depletion), was significantly higher than 
that of CD4+ cell-mediated disease (p < 0.01). 
Leukocyte Infiltration in CD4+ and CD8+ Cell-Mediated 
GVHD: Days 14-35 Influx of leukocytes into the skin, ob-
served with either strain combination, was first noted on day 14 
post-transplantation. Lymphocytes containing membrane-bound 
electron-dense cytoplasmic granules were observed within the der-
mal microvessels (Fig 2C, D). Endothelial cells were enlarged and 
protruded into the vessel lumens, indicative of "activation." Occa-
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sionallymphocytes adhered to endothelial cells and were penetrat-
ing microvessels. Diapedesis of lymphocytes attained maximum 
levels at days 21-35. 
In CD4+ cell-mediated GVHD, neutrophils accumulated within 
lumens of microvessels prior to accumulation oflymphocytes. Neu-
trophils predominated in microvessels at day 14, whereas the popu-
lation of intra lumenal lymphocytes gradually increased after day 14. 
In contrast to CD4+ cell-mediated GVHD, intralumenal neutro-
phils were consistently absent in CD8+ cell-mediated disease at the 
timepoints examined (Fig 2C). 
Lymphocytes with or without membrane-bound dense granules 
migrated into the epidermis (exocytosis) in both CD4+ and CD8+ 
cell-mediated GVHD. These lymphocytes, along with dendritic 
monocytes devoid of Birbeck granules, frequently surrounded dys-
keratotic keratinocytes (satellitosis). Many dyskeratotic cells, how-
ever, were unassociated with exocytotic lymphocytes in the sections 
examined (Figs 2D and 5) . The combined results for ultrastructural 
changes in CD4+ T-cell-mediated versus CD8+ T-cell-mediated 
GVHD are summarized in Table 1. 
Effect of Anti-TNF-a Ab on GVHD Mediated by CD4+ T 
Cells Irradiated DBA/2 mice transplanted with 2 X 106 B10.D2 
ATBM cells and 2 X 106 purified CD4+ T cells without Ab treat-
ments exhibited an incidence of lethal GVHD of 60% with a me-
dian s.ur:vival time (MS~) of 40 d (Fig 3a) . Similarly, transplanted 
mIce 1I1Jected weekly With 2 mg of CFA RIgG had 69% mortality 
and a MST of 36 d. In contrast, transplanted mice treated with 
weekly injections of 2 mg of anti - TNF-a Ah exhibited signifi-
cantly improved survival with 39% incidence oflethal GVHD and a 
MST of> 100 d (p = 0.05 in comparison to the untreated group and 
p < 0.01 compared to the CFA RIgG-treated group). Survival of the 
anti- TNF-a Ah-treated recipients was also significantly below the 
complete survival of DBA/2 mice transplanted with 2 X 106 
B 1 0.D2 AT13M cells alone (p < 0.0 1), indicating that TNF-a activ-
ity by itself was not likely to be the only factor responsible for 
GVHD mortality. 
As anticipated, treatment with anti- TNF-a Ab did not signifi-
cantly affect the degree of dermal mast cell degranulation (a pre-
sumed source of some of the locally produced TNF-a), which is 
observed at early timepoints (days 7 and 14) after BI0.D2 CD4+ 
T-cell transplantation in untreated DBA/2 mice (0.06 < P < 0.92) 
(Fig 3c). In l."ega.rd to. the kinetic development of dyskeratotic cells 
found 111 the skm (FIg 3b) , untreated mice undergoing CD4+ T-
cell -medl~ted GVHD exhibited significan tly greater numbers of 
dyskeratotic cells/mm than mice receiving ATBM alone on days 7, 
21,28, and 3 5 post-transplant (p < 0.01), and did not differ from 
mice administered control CFA RlgG (0.17 < P < 0.93). On the 
other hand, skin from animals treated with anti - TNF-a Ab be-
tween days 14 and 28 exhibited similar numbers of dyskeratotic 
cells to that of the ATBM control group and was significantly lower 
in comparison to untreated mice undergoing CD4+ T -cell -
mediated GVHD on days 21, 28, and 35 (p < 0.01). 
The mean ear thickness in untreated DBA/2 mice transplanted 
With BI0.D2 CD4+ T cells was significantly greater than that of 
mice given ATBM alone on days 21 and 35 (p < 0.01) post-trans-
plantation (Fig 3d). In contrast, the ear thickness in anti- TNF-a 
Ab-treated recipients was significantly diminished from the un-
treated group on days 21 and 35 (p < 0.01), but not different from 
the ATBM control at any timepoint (0.24 < P < 0.95) . Treatment 
of mice with CFA RIgG failed to diminish the ear thickness signifi-
cantly from the untreated control at any timepoint (0.07 < P < 
0.50). 
Effect of Auti-TNF-a Ab on GVHD Mediated by CD8+ T 
Cells Irradiated (800 cGy) CBA mice transplanted with 2 X 106 
BI0.BR ATBM cells and 2.5 X 106 purified CD8+ Tcells wi thout 
Ab treatments exhibited an incidence oflethal GVHD of 67% with 
a MST of 3 7 d (Fig 4a). Similarly transplanted mice injected weekly 
with 2 mg of CFA RIgG had 75% mortality and a MST of 31 d. 
Recipient mice treated with weekly injections of 2 mg of anti -
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Figure 1. Electron micrographs of early alterations (day 0-7) in Bl0.D2 -+ DBA/2 CD4+ cell-mediated GVHD. A) The initial events in CD4+ 
cell-mediated disease were extensive degranulation of m ast cells (Mc) and dyskeratosis (Dys), without evidence of influx of effector ce lls. V, microvessel; Mp, 
melanophage (bar, l/1m). B) Neither lymphocytes nor neutrophils were accumulated within the vessel (V) in this phase, although mast cells (Mc) were 
consistently degranulated. F, fibroblast; LD, lipid droplet (bar, 10 /1m) . C) Mas t cells exhibited complete degranulation, characterized by granule enlargement, 
membrane fusion of adjacent granules and between granule and plasma membranes, and electron lucency of granule matrices (bar, 1 tim) . D) Dyskeratotic cells 
were mainly concentrated on the basal cell layer. The nuclear chromatin of dyskeratotic cells was homogeneously aggregated (asterisks). Numerous vacuoles 
(V) were interspersed among abnormally condensed tonofilaments (Tf). Nu , nucleus; De, dermis (Bar, l/1m). 
TNF-Q Ab failed to show amelioration of mortality with 83% inci-
dence of leth al GVHD and a MSTof29 d (p = 0 .21 in comparison 
to CFA RI gG treatment). Moreover, when compared-to the un-
treated mice, anti - TNF-Q Ab administration could not signifi-
cantly decrease the number of dyskeratotic cells at any measured 
timepoint 7 - 28 d post- transplantation (0.27 < P < 0 .99) (Fig 4b) . 
Treatment with CFA RIgG also did not significantly affect the 
number of dyskeratotic cells, except at day 35 (p = 0 .02) . An analysis 
of the percentage of mast cells degranulating and of the extent of 
degranulation did not reveal any significant differences between the 
untreated and anti-TNF-Q Ab-treated transplant recipients at ei-
ther 7 or 14 d after GVHD induction (0.09 < P < 0.76)(Fig 4c). 
Likewise, no significant differences were found in ear thickness 
between any of the experimental groups, except between untreated 
and either CFA RI g-treated or ATBM mice on day 7 (p < 0.03) 
(Fig 4d). 
The sequential developments of ultras tructural changes in the 
skin were also similar between untreated CD8+ T -cell- mediated 
GVHD-induced CBA mice and those trea ted with anti - TNF-a 
Ab. Anti - TNF-Q Ab treatment did not influence the quality of 
mast cell degranul ation, vascular activation, diapedesis of leuko-
cytes, and the subsequent exocytosis of lymphocytes. 
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Figure 2. Sequential ultrastructure of early B10.BR -> CBA CD8+ cell-mediated GVHD (day 0- 7) . Dyskeratosis and hypogranulation of masrcells preceded 
influx of effector lymphocytes in CD8+ cell-mediatcd disease. A) The ultrastructural features of dyskeratotic cells in CD8+ cell-mediated GVHD were 
identical to that in CD4+ cell-mediated disease. Nu, nucleus; asterisks, homogeneously aggregated nuclear chromatin; V, vacuoles; Tf, tonofilaments (bar, 1 
J.lm). B) A hypogranulated mast cell (Mc) at day 7 of CD8+ cell-mediated GVHD, without evidence of active degranulation. Mp, melanophage (bar,S Jim). 
C) Only lymphocytes (Ly), with or without mcmbrane-bound dense granules, were accumulated within microvessels at day 14 of CD8+ cell-mediated 
GVHD. V, veil cell; E, endothelial cel l (bar = 5 Jim) . D) The ultrastructure of exocytotiC lymphocytes (Ly) often containing membrane-bound dense 
cytoplasmic granules in CD8+ cell-mediated GVHD was similar to that of CD4+ cell-mediated disease (bar, 1 pm). 
Effect of Genetic Mast Cell Depletion on CD8+ T-cell-
JUediated GVHD B6 WWV and B6+/+ mice were irradiated (850 
cGy) and transplanted with 2 X 106 C3H.SW ATBM cells and 
4 X 106 purified C3H.SW CD8+ T cells or with ATBM alone (Fig 
6a). The incidence of GVHD mortality was moderate in both 
groups of recipients, with significantly greater survival in the 
B6WWv recipients (50%, 96-d MST versus 30%, 60-d MST for 
B6+/+ mice) (p < 0.03). 
Sequential histopathologic analysis of skin samples from both 
B6 WWv and B6+/+ mice undergoing development of GVHD indi-
cated a marked diminution in the number of dyskeratotic cells/mm 
in the skin ofB6WWv recipients in comparison to B6+/+ mice (Fig 
6b). The differences were statistically significant on days 14,21, and 
28 post-transplantation (p < 0.01). The number of dyskeratotic cells 
in the skin ofB6WWv recipients of C3H.SW CD8+ T cells exhib-
ited a gradual increase from day 21 on, reaching the level found in 
B6+/+ recipients by day 40 (p = 0.25) . The number of dyskeratotic 
cells in the skin of B6WWv mice undergoing GVHD was signifi-
cantly higher than B6WWv mice given ATBM alone on day 40 
(p < 0.01) and approached significance on both days 21 and 30 
post-transplantation (0.05 < P < 0.06). 
Ultrastructurally, at the time of transplantation (day 0), no defin-
itive mast cells could be identified in the skin ofB6WWv recipients, 
although occasional mononuclear cells possibly representing mast 
cell precursors were observed around dermal microvessels (Fig 7 A). 
These cells were characterized by oval nuclei, dendritic cytoplasmic 
processes, a number of poorly defined vesicles, cytoplasmic vacuoles 
that occasionally contained moderately electron-dense granular and 
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Figure 3. Effect of anti-TNF-a Ab treatment on development of CD4+ T -cell-mediated GVHD. a) Survival and incidence of GVHD. DBA/2 mice were 
irradiated (900 cGy) and injected intravenously with either 2 X 106 B10.D2 ATBM cells alone (- -; n = 14) orwith 2 X 106 B10.D2 CD4+Tcells. The latter 
mice were divided into three groups, the first left untreated (- ; n = 15), the second given anti-TNF-a Ab (2 mg intravenously, 1 h before cells were 
injected; 2 mg intraperitoneally weekly thereafter till day 42) ( • .•.• .•.• .• ; n = 18), and the third treated with control CFA RIgG (2 mg intravenously, 1 h 
before cells were injected; 2 mg intra peritoneally weekly thereafter until day 42). ( ." .... """"" .. ",,.... ; n = 16). b) Sequential analysis of the mean ± SEM number of 
dyskeratotic cells/linear mm of skin from DBA/2 mice of the four groups described in (a) from days 0-35 post-transplantation; an average of n = 6 for 
untreated (0) and anti-TNF-aAb (0), n = 3 for CFA RIgG (11), and n = 4 for ATBM (e). c) The mean±SEM percentage of mast cells degranulatingand the 
extent of degranulation in the skin ofDBA/2 mice from the untreated~; n = 7), anti- TNF-a Ab treated (~; n = 6, d 7 and n = 5, d 14), and ATBM (0 ; n = 3) 
groups at days 7 and 14 post-transplantation. d) Sequential analysis of the mean ± SEM ear thickness from DBA/2 mice of the four groups described in (b) 
from days 0-35 post-transplantation (n = 3 for all groups and timepoints). 
flocculent material, and fibronexus-like electron-dense plaques (Fig 
7B). By day 14, these perivascular cells exhibited widening of rough 
endoplasmic reticulum (rER) and had developed increased numbers 
of moderately electron-dense granular matrices within membrane-
bound cytoplasmic vacuoles (Fig 7C). By days 30- 40, mast cell-like 
cells and occasional definitive mast cells containing granular matri-
ces accompanied by electron-lucent halos were evident about super-
ficial vessels (Fig 7D). These latter cells contained nu~rous elec-
tron-dense granules with some evidence of degranulation, 
characterized by granule enlargement, membrane fusion, and de-
creased electron density of granular matrices (Fig 7D). 
The sequential ultrastructural appearance of mast cells in control 
B6+/+ mice undergoing GVHD development were similar to those 
previously described for BtO.BR...-+ CBA CD8+ T-cell-mediated 
disease. A small number of completely de granulated mast cells and a 
large number of mast cells with decreased numbers of granules, but 
without evidence of active degranulation, were observed on day 7 
and day 14 in diseased B6+/+ recipients. B6+/+ transplant recipients 
exhibited dermal and epidermal accumulation of lymphocytes with 
associated sequential ultrastructural alterations that were indistin-
guishable from CD8+ cell-mediated disease in the BtO.BR...-+ CBA 
combination. Transplanted B6 WWV mice, on the other hand, did 
not demonstrate similar cellular infiltrates and associated changes 
until days 30-40, indicating a delay in histologic evidence of dis-
ease, which coincided with the appearance of granulated mast cells. 
DISCUSSION 
This study was designed to address whether mast cells, or their 
cytokine products (TNF-a), playa role in the early evolutionary 
stages of experimental acute GVHD. In the anti-minor H antigen 
GVHD model elicited by CD4 + effector T cells, marked degranula-
tion of mast cells and associated dyskeratosis of keratinocytes char-
acterized the early evolutionary stages of disease and preceded the 
influx of effector lymphocytes . Degranulation of mast cells was first 
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Figure 4. Effect of anti - TNF·a Ab on development of CD8+T -cell-mediated GVHD. a) Surviv~l and incidence ofGVHD. CBA mice were irradiated (800 
cGy) and injected intravenously with either 2 X 106 BI0.BR ATBM cells alo~e (- - -; ~1 = 14) orwlth 2.5 X 106 BI0.BR CD8+T cells. The latter mice were 
divided into three groups. the first left untreated (-- ; n = 15), the second gIven antl - TNF-a Ab (2 mg IIltravenously. 1 11 before cells were injected; 2mg 
intraperitoneally weekly thereafter till day 42) (......... ; n = 18), and the third treated with control CFA ~gG (2mg intrav~nously. 1 h before cells were 
injected; 2 mg intraperitoneally weekly thereafter till day 42) ( ............................ ; n = 16). b) SequentIal analysIs of the mean ± SEM number of dyskeratotic 
cells/linear mm of skin from CBA mice of the four groups described in (a) from days 0- 35 post-transplantation; tJ = 3 for untreated (-0-). anti-TNF-a Ab 
(0), CFA RlgG (11), and ATBM (.) groups. c) The mean ± SEM percentage of mast cells degranulatmg and the extent of degranulation in the skin of CBA 
mice from the untreated (II). anti- TNF-a Ab treated (~) , and ATBM (0) groups at days 7 and 14 post-transplantation (n = 3 for all groups). d) Sequential 
analysis of the mean ± SEM ear thickness from CBA mice of the four groups described in (b) from days 0-35 post-transplantation (n = 3 for all groups and 
timepoints) . 
demonstrable at day 7 post-transplantation, whereas by day 14, no-
table intravascular accumulation ofleukocytes and extravasation of 
lymphocytes, followed by exocytosis and focal satellitosis in the 
epidermis, were observed. These findings suggest a temporal link-
age berween the degranulation of mast cells and early epidermal 
injury before the influx of effector CD4+ lymphocytes, and is con-
sonant with previous studies linking mast cell degranulation and 
TNF-a liberation to the influx of helper T cells [29]. Stuart and 
co-workers [30] have previously demonstrated that the number of 
mast cells significantly increased at early timepoints (days 6 and 8) in 
both DA and Brown-Norway rats undergoing GVHD induction, 
but significantly decreased at later timepoints. The observations in 
both the rat and the current murine models raises the possibility that 
a humoral factor produced by allostimulated effector cells may in-
duce the proliferation, activation, and degranulation of mast cells in 
the early phase of GVHD. Indeed, the production of "histamine-
releasing factors" by activated T cells has been proposed to explain 
how mast cells are induced to degranulate during the early phase of 
delayed hYf.ersensitivity reactions and in experimental chronic 
GVHD [31 . In our model, such humoral factors would be expected 
to be produced in extracutaneous sites at day 7, because lymphocytes 
were not observed in lesional skin at this juncture. By day 14 and 
beyond, when inflammatory cells infiltrate skin, both systemic as 
well as locally produced factors could facilitate mast cell degranula-
tion. 
The temporal relationship observed in this study berween mast 
cell degranulation and dyskeratosis would suggest that soluble fac-
tors (cytokine/s) released during the process of degranulation might 
contribute to keratinocyte il~ury. TNF-a is one such candidate to 
mediate this effect, as it appears to be produced and released by 
activated murine mast cells [11 - 13]. Similar observations have been 
made in our own laboratory with human skin samples, indicating 
that a) TNF-a is predominantly synthesized, stored, and released by 
dermal mast cells; b) keratinocytes and dermalmonocytes express 
very little constitutive TNF-a by comparison; and c) based on ul-
trastructural and immunohistochemical evidence. mast cell de gran-
458 MURPHY ET AL THE JOURNAL OF IN VESTIGATIVE DERMATOLOGY 
Figure 5. Electron micrographs of exocytosis and satellitosis in CD4+ cell-mediated GVHD (days 14-28). A) Lymphocytes (Ly) and indeterminate 
mononuclear cells (Ie) are aggregated within the lower layers of the epidermis where the majority of epidermal injury is noted. K, keratinocyte; arrowhead, 
derm~l-epidermal junction (bar, 5 11m) . B) Several indeterminate mononuclear cells and lymphocytes are grouped around dyskeratotic cell (Dys), evidence of 
"satel litosis." M, melanocyte (bar, 5 11m). 
ulation closely correlates with released amounts ofTNF-a [14] . In 
regard to the potential involvement of TNF-a in dyskeratosis, cy-
tostatic effects of either TNF-a,lymphotoxin, or gamma interferon 
(IFN-y) on cultured human keratinocytes have been reported 
[6,32]. These cytokines independently inhibit human keratinocyte 
DNA synthesis and the combined treatment with either TNF-a or 
lymphotoxin and IFN-y enhances keratinocyte cytostasis (although 
not necessarily necrosis/dyskeratosis) and after 2- 3 d leads to exag-
gerated changes in cell morphology [6]. In addition, preliminary 
data (Murphy and Tharp, unpublished) suggest that TNF-a in 
combination with certain mast cell enzymes, such as chymase, are 
Table I. Summary of Morphologic Findings in CD4+ 
and CD8+ Mediated Acute GVDH 
Mast cell degranulation 
Severity 
Extent 
Dyskeratosis 
Endothelium 
Neutrophils 
Lymphocytes 
Epidermotrophism 
Satellitosis 
Early (day 7), 
moderate - severe 
More focal 
Present (before leu-
kocytic infiltration) 
Activated phenotype 
(by day 14) 
Intralumenal (day 14) 
Gradual increase 
(days 14-35) 
Prominent 
Variable' 
CD8+ 
Early (day 7), mild 
More diffuse 
Present (before leu-
kocytiUnfil tration) 
Activated phenotype 
(by day 14) 
None observed 
Gradual increase 
(days 14-35) 
Less prominent 
Variable' 
• The designation "variable" indicates that not all epidennotrophic lymphocytes 
were in apposition to degenerating or necrotic keratinocytes. nor were all degenerating 
or necrotic keratinocytcs in apposition to cpidcrmotropic lymphocytes. 
toxic to human keratinocytes ill vitro . These findings, along with 
recent evidence that IFN-a, -fl, and -y upregulate TNF-a receptors 
fit, perhaps, with a contributing role for TNF-a in the development 
of epidermal GVHD [33] . 
Recent studies by Piguet and co-workers [5,7] have suggested a 
role for TNF-a in the epithelial alterations generated in a semi-
allogeneic MHC murine GVHD model, based on the findings that 
the injection of anti- TNF-a IgG remarkably improved mortality 
and reduced the number of necrotic epidermal cells, although it 
failed to prevent T-cell activation and development of GVHD. 
They speculated that the source of TNF-a in GVHD must be re-
lated to cellular alterations in the dermis, such as from stimulated T 
lymphocytes [34], macrophages [35], and/or natural killer cells 
[36-38]. In the present study, although immunohistochemical 
confirmation is lacking, the consistent observation of infiltrating 
lymphocytes containing membrane-bound granules is consistent 
with our previous structural and immunocytochemical observations 
that large granular lymphocytes may play an important role in the 
effector phase of this disease [38]. 
The present study demonstrates that anti - TNF-a Ab treatment 
can significantly ameliorate mortality and reduce the number of 
dyskeratotic epidermal cells associated with a CD4+ T-cell-
mediated GVHD response to minor H antigens. In addition to 
potential inhibition of direct TNF-a-mediated keratinocyte toxic-
ity, the mechanism for this anti - TNF-a Ab treatment effect also 
may involve decreased recruitment and diapedesis of effector lym-
phocytes. For example, anti- TNF-a Ab treatment significantly 
diminished the ear thickness, a parameter that correlates closely 
with the quantity of cellular infiltration in this model. In human 
skin, TNF-a is known to induce endothelial adhesion molecules, 
such as E-selectin [14,39,40] and vascular cell adhesion molecule-1 
(VCAM-1) [41], which may playa critical role in recruiting effector 
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Figure 6. Effect of genetic mast cell dep letion on CD8+ T -ccll- mediated 
GVHD. a) Survival and incidence of GVHD. 2 X 106 C3H.SW ATBM 
cells were injected i.v. into irradiated (850 cGy) B6WWv (- -) and B6+/+ 
( • .•.•.•. •.• ) mice. alone or with 4 X 106 C3H.SW CD8+ T cel ls 
(CD8~B6WWv (-); CD8~B6+/+ ( " ................. "'" .. " ); n = 10 for all 
groups. b) Sequential analys is of the mean ± SEM number of dyskeratotic 
cells/linear mm of skin from the four groups described in (a) from days 
0-35 post-transplantation (n = 3 for all groups and timepoints). 
ATBM-->B6WWv (-_-) . ATBM--->B6+/+ (-[ ]-). (CD8-->B6WWv (-e-). 
CD8---B6+f+ (-0 -). 
leukocytes to the skin microvesscls about which mast cells normally 
reside . 
Aside from toxic effects on keratinocytes and induction of endo-
thelial-leukocyte adhesion molecules. TNF-a may also contribute 
to the regulation and interaction of effector leukocytes and target 
cells in acute GVHD. Resting T cells do not normally express 
TNF-a receptors but they are inducible upon activation'[42]. Once 
receptors are present, TNF-a can then enhance expression of the a 
subunit of the IL-2 receptor and can synergize with IL-2 with re-
spect to both stimulation of T -cell proliferation and production of 
IFN-y [42]. In turn. IFN-y can upregulate TNF-a receptors, among 
other surface molecules, and increase the target cell susceptibility to 
TNF-a-mediated cytotoxicity [43]. In addition TNF-a-induced 
production of other cytokines including IL-l [44], IFN-fJ2/IL6 
l45], IFN-fJl [46]' and granulocyte macrophage-colony stimulating 
factor GM-CSF [47] may contribute to the activation of effector 
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leukocytes and enhancement of the immune response. In the 
present study, the inability of anti - TNF-a pretreatment to inhibit 
dyskeratosis at day 7 in CD4+ T -cell-mediated disease suggests the 
possibility that factors other than, or in addition to, this cytokine 
(perhaps local mast cell proteases or circulating systemic factors) 
may contribute to these early alterations. On the other hand , the 
efficacy of this treatment at later timepoints associated with leuko-
cyte infiltration raises the possibility that TNF-a is primarily im-
portant for the trafficking of effector lymphocytes to prospective 
target sites and for the modulation of direct effector-target cell 
interactions. At these later timepoints, anti- TNF-a Ab treatment 
may inhibit TNF (either -a or -fJ, because both antisera and MoAb 
generated to TNF-a crossreact with TNF-fJ [48]) produced from a 
variety of cellular sources, including mast cells, keratinocytes, mon-
ocyte/macrophages, and by effector lymphocytes that migrate into 
the epidermis, where they are spatially associated with target epi-
thelial cells. 
In the Bl0.BR ~ CBA GVHD model elicited by CD8+ effector 
cells, the early phase was characterized by mast cells that exhibited a 
low number of granules but were devoid of ultras tructural evidence 
of degranulation in comparison to those cells found in CD4+ cell-
mediated disease. We currently do not know the significance of 
these hypogranulated mast cells, although it seems likely that they 
may represent previously degranulated cells not "captured" in the 
timepoint examined. In contrast to CD4+ T-cell-mediated 
GVHD, the present study suggests that TNF-a is irrelevant to 
epithelial injury and inflammatory events in CD8+ T-cell -
mediated GVHD development. The basis for this notion is that 
anti - TNF-a Ab failed to affect either survival or the number of 
dyskeratotic cells in the skin at any timepoint. Interestingly, the 
previous observations of more extensive gut involvement in CD4+ 
T -cell-mediated GVHD in comparison to CD8 disease [30,49,50] 
raise the possibility that participation of TNF in the former may 
contribute to the observed differences in severity of target cell injury 
at this site. 
The effect of genetic depletion of mast cells on CD8+ T -cell-
mediated GVHD in the C3H .SW ~ B6WW v strain combination 
can be summarized as a delay in disease onset that correlated with 
the appearance of granulated mast cells. This was marked by a sig-
nificant prolongation of survival and a shift to later timepoints 
post-transplantation with regard to the development of intravascu-
lar accumulation and diapedesis of lymphocytes and an increased 
number of dyskeratotic cells, compared with the C3H.SW ~ B6+/+ 
control strain combination. Eventual disease onset and progression 
in B6WW v mice correlated with the appearance of granule-con-
taining dermal mast cells at later timepoints. In B6WW v mice, the 
fixed precursors of mast cells in the skin are markedly depleted [51] 
and bone marrow transplantation from B6+/+ mice can dramatically 
increase the number of mas t cells between 35 - 75 d post-transplan-
tation [52]. The W locus has been shown to be allelic with the c-kit 
proto-oncogene and encodes for a protein that is a member of the 
transmembrane tyrosine kinase receptor family [53,54] . Therefore, 
it is likely that the recovery of mast cells in transplanted B6WWv 
mice is due to the proliferation and differentiation of precursor cells 
from the donor bone marrow [51 ,55]. Alternatively, B6WW v mice 
may possess a few precursor mast cells in their skin that can be 
promoted to differentiate by donor-derived humoral factors or in-
ducer cell s without invo lving the c-kit pathway. Support for this 
notion has come from both il1 vitro stem cell proliferation experi-
ments [56] and an il1 J/ illO model in which local development of a 
large number of mas t cells at sites of idiopathic chronic dermatitis in 
B6WWv mice, independent of bone marrow transplantation, has 
been reported [57] . In this case, the etiology of the chronic dermati-
tis that had developed in the B6WWV mice was unknown and the 
authors suggested that putative growth factors produced in the 
course of disease might participate in the local development of mast 
cells. 
In conclusion, the present study suggests that factors released by 
degranulation of mast cells, elicited by both CD4+ and CD8+ effec-
tor T cells in the initial phases of GVHD, play an important role in 
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Figure 7. Ultrastructural analysis of mast cells in B6WWv mice. A) Mononuclear cells devoid of mast cell granules (rectattgl4lar area) were observed around 
dermal microvessels at the time of transplantation (day 0). Ep, epidermis; D, dermal dendrocyte; P, pericyte;E, endothelial cell (bar, S 11m). B) High power view 
of agranular mononuclear cells depicted in rectangular area of (A). These cells displayed dendritic cytoplasmic processes and contained poorly defined 
cytoplasmic vesicles, fibronexus-like electron-dense plaques (arrow/leads, high power view shown in inset (A); bar, 0.5 11m), and occasional vacuoles containing 
moderately electron-dense granular material (bar, 111m). High power view of the rectatlgular area b is shown in (B; bar, 0.5 11m). C) Mononuclear cell around 
micro vessel on day 14 exhibits marked widening of rough endoplasmic reticulum and moderately electron-dense granular matrices (arrow). P, pericyte; E, 
endothelial ce ll (bar, 111m). D) A definitive mast cell on day 40, which contained some electron-dense granules (asterisks) and moderately degranulated 
matrices (X4,000; bar,S 11m). Inset, high power view of rectangular area (bar, 111m). 
early epithelial injury that is independent of direct contact with 
donor lymphocytes . The administration of anti- TNF-ex Ab to re-
cipient mice failed to abrogate this ea~ly. injury in b?th types ?f 
GVHD, but could diminish the level of mJury at later tlmepomts m 
CD4+ T -cell- mediated disease. Dermal mast cells may still playa 
critical role in the early and direct development of dyskeratosis, and 
may also be important in indirectly facilitating effector cell tra£?ck-
ing via endothelial activation. At least in CD8+ T-cell-medtated 
GVHD, the presence of mast cells appears to be requ~d for the 
development of disease. Overall, these findings suggest that the 
potential clinical application of anti - TNF-ex Ab treatment for pa-
tients with severe acute GVHD may have limited value, and may be 
most effective in decreasing skin and gut lesions induced by CD4+ 
alloreactive T cells. The results of a recent clinical pilot study with 
anti- TNF-ex Ab treatment is consistent with this notion, in that 
although in the majority of cases the treatment was ineffective in 
preventing GVHD-related fatality, beneficial responses were fOllnd 
predominantly in the gut and skin [58] . We speculate that suppres-
sion of mast cell activity, in general, may have an even broader effect 
on the development and natural progression of GVHD. 
This work was supported by Vllited Public Healt/, Service Gratlts CA-38951 , 
HD-21926, CA-40358, atld CA-38355 from the Natiotral Imtillltes of Health . 
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